The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.
 
Matthew Steven Davids
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Genentech; InCyte; Janssen; MEI Pharma; Merck; Pharmacyclics; TG Therapeutics
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); MEI Pharma (Inst); Pharmacyclics (Inst); Surface Oncology (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - TG Therapeutics
 
John Francis Seymour
Consulting or Advisory Role - Roche/Genentech
Research Funding - Abbvie/Genentech
 
Andrew Warwick Roberts
Research Funding - AbbVie (Inst); BeiGene (Inst); Janssen (Inst); Merck (Inst); Servier (Inst)
 
Barbara Eichhorst
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen-Cilag; Novartis; Roche
Speakers' Bureau - Abbvie; Celgene; Gilead Sciences; Janssen-Cilag; Roche/Genentech
Research Funding - Abbvie; Gilead Sciences; Janssen; Roche
Travel, Accommodations, Expenses - GlaxoSmithKline; Mundipharma; Roche
 
Thomas J. Kipps
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie
 
Anthony R. Mato
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Celgene; Janssen; Prime Oncology; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); DTRM (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Regeneron (Inst); TG Therapeutics (Inst)
 
Stephan Stilgenbauer
Consulting or Advisory Role - AbbVie; Amgen; Boehringer Ingelheim; Celgene; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Janssen; Mundipharma; Novartis; Pharmacyclics; Roche; Sanofi
Research Funding - Abbvie; Amgen; Boehringer Ingelheim; Celgene; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Janssen; Mundipharma; Novartis; Pharmacyclics; Roche; Sanofi
Travel, Accommodations, Expenses - Abbvie; Amgen; Boehringer Ingelheim; Celgene; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Janssen; Mundipharma; Novartis; Pharmacyclics; Roche; Sanofi
 
Mehrdad Mobasher
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Monali Bhardwaj Desai
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jalaja Potluri
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
German E. Pena
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Maria E. Verdugo
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jacqueline Nielsen
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Aimee Cyr
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Leanne Lash Fleming
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Michael J. Hallek
Honoraria - Abbvie; Gilead Sciences; Janssen; Roche
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen; Roche
Speakers' Bureau - Abbvie; Gilead Sciences; Janssen; Roche
Research Funding - Abbvie; Gilead Sciences; Janssen; Roche
Travel, Accommodations, Expenses - Janssen; Roche